2018
Factors affecting local regrowth after watch and wait for patients with a clinical complete response following chemoradiotherapy in rectal cancer (InterCoRe consortium): an individual participant data meta-analysis
Chadi SA, Malcomson L, Ensor J, Riley RD, Vaccaro CA, Rossi GL, Daniels IR, Smart NJ, Osborne ME, Beets GL, Maas M, Bitterman DS, Du K, Gollins S, Myint A, Smith FM, Saunders MP, Scott N, O'Dwyer ST, de Castro Araujo RO, Valadao M, Lopes A, Hsiao CW, Lai CL, Smith RK, Paulson EC, Appelt A, Jakobsen A, Wexner SD, Habr-Gama A, Julião G, Perez R, Renehan AG. Factors affecting local regrowth after watch and wait for patients with a clinical complete response following chemoradiotherapy in rectal cancer (InterCoRe consortium): an individual participant data meta-analysis. The Lancet Gastroenterology & Hepatology 2018, 3: 825-836. PMID: 30318451, DOI: 10.1016/s2468-1253(18)30301-7.Peer-Reviewed Original ResearchConceptsClinical complete responseIndividual participant dataComplete responseLocal regrowthRectal cancerCumulative incidenceParticipant dataNeoadjuvant chemoradiotherapyHazard ratioSustained clinical complete responseProportion of patientsCenter heterogeneityRecent systematic reviewCox frailty modelStage cT1CT2 tumorsMajor surgeryPrimary outcomeTreatment characteristicsChemoradiotherapyLower riskPatientsStudy heterogeneitySystematic reviewNovel management strategies
2017
Biomarkers that Predict Response to Neoadjuvant Chemoradiation in Locally Advanced Rectal Cancer
Oh P, Du K. Biomarkers that Predict Response to Neoadjuvant Chemoradiation in Locally Advanced Rectal Cancer. Current Colorectal Cancer Reports 2017, 13: 276-283. DOI: 10.1007/s11888-017-0376-3.Peer-Reviewed Original ResearchAdvanced rectal cancerRectal cancerNeoadjuvant chemoradiationComplete responsePathologic complete responseStandard of careBowel functionNeoadjuvant therapyOverall survivalTumor responsePotential complicationsChemoradiationBiologic factorsTreatment correlatesCancerSurgeryRecent reportsCurrent literatureBiomarkersResponseComplicationsPatientsTherapyCare
2015
Anal Cancer Outcomes in Patients Treated With Intensity Modulated Compared to 3-Dimensional Radiation Therapy
Cooper B, Bitterman D, Grew D, No H, Sanfilippo N, Du K. Anal Cancer Outcomes in Patients Treated With Intensity Modulated Compared to 3-Dimensional Radiation Therapy. International Journal Of Radiation Oncology • Biology • Physics 2015, 93: e165. DOI: 10.1016/j.ijrobp.2015.07.972.Peer-Reviewed Original Research
2014
Significantly Worse Colostomy-Free Survival in Human Immunodeficiency Virus–Positive Patients After Definitive Chemoradiation for Anal Cancer
Grew D, Bitterman D, Leichman C, Leichman L, Du K. Significantly Worse Colostomy-Free Survival in Human Immunodeficiency Virus–Positive Patients After Definitive Chemoradiation for Anal Cancer. International Journal Of Radiation Oncology • Biology • Physics 2014, 90: s398-s399. DOI: 10.1016/j.ijrobp.2014.05.1273.Peer-Reviewed Original Research
2009
The Impact of Marital Status and Race in Patients Enrolled in Radiation Oncology Group (RTOG) Prostate Cancer Trials
Du K, Bae K, Movsas B, Gamerman V, Coyne J, Bryan C, Watkins-Bruner D. The Impact of Marital Status and Race in Patients Enrolled in Radiation Oncology Group (RTOG) Prostate Cancer Trials. International Journal Of Radiation Oncology • Biology • Physics 2009, 75: s131. DOI: 10.1016/j.ijrobp.2009.07.313.Peer-Reviewed Original Research
2007
Patterns and Levels of Hypoxia in Head and Neck Squamous Cell Carcinomas and Their Relationship to Patient Outcome
Evans SM, Du KL, Chalian AA, Mick R, Zhang PJ, Hahn SM, Quon H, Lustig R, Weinstein GS, Koch CJ. Patterns and Levels of Hypoxia in Head and Neck Squamous Cell Carcinomas and Their Relationship to Patient Outcome. International Journal Of Radiation Oncology • Biology • Physics 2007, 69: 1024-1031. PMID: 17967299, PMCID: PMC2737259, DOI: 10.1016/j.ijrobp.2007.04.067.Peer-Reviewed Original ResearchConceptsSquamous cell carcinomaCell carcinomaPatient outcomesNeck squamous cell tumorsNeck squamous cell carcinomaEvent-free survival timeShorter event-free survival timePositron emission tomographic studiesSquamous cell tumorsLevels of hypoxiaEmission tomographic studiesNodal statusOverall survivalTreatment regimenPrognostic significanceCell tumorsPrimary headMajority of cellsSurvival timeOral cavityHypoxia markersQuantitative immunohistochemistryEF5 bindingSevere hypoxiaPatients
2006
Preliminary results of interstitial motexafin lutetium‐mediated PDT for prostate cancer
Du KL, Mick R, Busch TM, Zhu TC, Finlay JC, Yu G, Yodh AG, Malkowicz SB, Smith D, Whittington R, Stripp D, Hahn SM. Preliminary results of interstitial motexafin lutetium‐mediated PDT for prostate cancer. Lasers In Surgery And Medicine 2006, 38: 427-434. PMID: 16788929, DOI: 10.1002/lsm.20341.Peer-Reviewed Original ResearchConceptsInterstitial photodynamic therapyProstate adenocarcinomaProstate cancerPhotodynamic therapyRecurrent prostate adenocarcinomaSolid organ diseaseSubsequent tissue necrosisOrgan diseaseDrug levelsPreclinical studiesClinical experienceSTUDY DESIGN/MATERIALSTissue necrosisDose distributionDESIGN/MATERIALSPhase IAdenocarcinomaHuman subjectsProstateCancerTreatmentUniversity of PennsylvaniaDose variationComprehensive treatmentPatients